Trademark Overview
On Friday, March 27, 2026, a trademark application was filed for BIODELPHIS THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the BIODELPHIS THERAPEUTICS trademark a serial number of 79453338. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, July 2, 2026. This trademark is owned by Biodelphis Therapeutics SA. The BIODELPHIS THERAPEUTICS trademark is filed in the Pharmaceutical Products, Advertising, Business and Retail Services, Treatment & Processing of Materials Services, and Computer & Software Services & Scientific Services categories with the following description:
Retail or wholesale services for pharmaceutical, biotechnological and veterinary preparations as well as for medical supplies; all of the foregoing, with the exception of retail, wholesale or consulting services concerning diagnostic medical devices, genetic testing reagents or equipment intended for neurological research or diagnosis
Processing and manufacturing of biochemical and pharmaceutical products for third parties and related consulting services; custom manufacturing of pharmaceutical products to order and according to a client's specifications; all of the foregoing, with the exception of services involving DNA sequencing, gene cloning, genetic modification of cells or nanotechnological processes intended for administering therapeutic agents
Research and development for the pharmaceutical industry; research and development in the field of biotechnology; biotechnology research; research in biotechnology; biomedical research services; pharmaceutical research and development services; medical research services; scientific research services for medical purposes; scientific and technological services, as well as related research and development services; all of the above, excluding medical or clinical research in the field of genetic or neurological diseases, as well as services related to genetic engineering, DNA manipulation, or drug delivery using nanotechnology
Pharmaceutical preparations, namely antibody-peptide inhibitor conjugates intended for use in oncology as well as for the treatment of osteoporosis and autoimmune diseases; Dietary supplements for humans; all of the foregoing, excluding pharmaceutical or biotechnological preparations intended for genetic or neurological diagnosis or treatment, or involving genetic engineering, DNA manipulation, or drug delivery systems based on nanotechnology
